The innovative medicines initiative: a public private partnership model to foster drug discovery

Comput Struct Biotechnol J. 2013 Nov 27;6:e201303017. doi: 10.5936/csbj.201303017. eCollection 2013.


The Innovative Medicines Initiative (IMI) is a large-scale public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI aims to boost the development of new medicines across Europe by implementing new collaborative endeavours between large pharmaceutical companies and other key actors in the health-care ecosystem, i.e., academic institutions, small and medium enterprises, patients, and regulatory authorities. Currently there are more than 40 IMI projects covering the whole value chain of pharmaceutical R&D, but with a strong focus on drug discovery, as an ideal arena where the PPP concept of pre-competitive collaboration can rapidly deliver results. This article review recent achievements of the IMI consortia of relevance to drug discovery, providing proof-of-concept evidence for the efficiency of this new model of collaboration.

Keywords: attrition rate; bottlenecks; drug efficacy; drug safety; knowledge management; pharmaceutical industry.